The European Commission approved Fruzaqla (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
In the rapidly evolving field of oncology, the integration of big data and artificial intelligence is revolutionizing our approach to cancer research and treatment. The future of precision oncology requires integrating computational approaches with clinical practice.
